Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O60500
UPID:
NPHN_HUMAN
Alternative names:
Renal glomerulus-specific cell adhesion receptor
Alternative UPACC:
O60500; A6NDH2; C3RX61
Background:
Nephrin, known as a renal glomerulus-specific cell adhesion receptor, plays a crucial role in kidney function and skeletal muscle formation. It is pivotal in developing the kidney glomerular filtration barrier, regulating vascular permeability, and anchoring the podocyte slit diaphragm to the actin cytoskeleton.
Therapeutic significance:
Nephrin's involvement in Nephrotic syndrome 1, characterized by severe proteinuria and potential progression to end-stage renal failure, highlights its therapeutic significance. Understanding Nephrin's role could lead to novel treatments for this debilitating condition.